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Background: HIV-1 is inhibited early after entry into cells expressing some simian orthologues of the tripartite motif
protein family member TRIM5α. Mutants of the human orthologue (TRIM5αhu) can also provide protection against
HIV-1. The host protein cyclophilin A (CypA) binds incoming HIV-1 capsid (CA) proteins and enhances early stages
of HIV-1 replication by unknown mechanisms. On the other hand, the CA-CypA interaction is known to increase
HIV-1 susceptibility to restriction by TRIM5α. Previously, the mutation V86M in the CypA-binding loop of HIV-1 CA
was found to be selected upon serial passaging of HIV-1 in cells expressing Rhesus macaque TRIM5α (TRIM5αrh).
The objectives of this study were (i) to analyze whether V86M CA allows HIV-1 to escape mutants of TRIM5αhu, and
(ii) to characterize the role of CypA in the resistance to TRIM5α conferred by V86M.
Results: We find that in single-cycle HIV-1 vector transduction experiments, V86M confers partial resistance against
R332G-R335G TRIM5αhu and other TRIM5αhu variable 1 region mutants previously isolated in mutagenic screens.
However, V86M HIV-1 does not seem to be resistant to R332G-R335G TRIM5αhu in a spreading infection context.
Strikingly, restriction of V86M HIV-1 vectors by TRIM5αhu mutants is mostly insensitive to the presence of CypA in
infected cells. NMR experiments reveal that V86M alters CypA interactions with, and isomerisation of CA. On the
other hand, V86M does not affect the CypA-mediated enhancement of HIV-1 replication in permissive human cells.
Finally, qPCR experiments show that V86M increases HIV-1 transport to the nucleus of cells expressing restrictive
TRIM5α.
Conclusions: Our study shows that V86M de-couples the two functions associated with CA-CypA binding, i.e. the
enhancement of restriction by TRIM5α and the enhancement of HIV-1 replication in permissive human cells. V86M
enhances the early stages of HIV-1 replication in restrictive cells by improving nuclear import. In summary, our data
suggest that HIV-1 escapes restriction by TRIM5α through the selective disruption of CypA-dependent, TRIM5α-
mediated inhibition of nuclear import. However, V86M does not seem to relieve restriction of a spreading HIV-1
infection by TRIM5αhu mutants, underscoring context-specific restriction mechanisms.* Correspondence: berthoux@uqtr.ca
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TRIM5α was isolated as a retroviral restriction factor in
2004 [1] and acts within the post-entry, pre-integration
window [2,3]. The viral molecular target of TRIM5α is
the correctly matured N-terminal domain of capsid (CA)
proteins forming the outer surface of the retroviral core
[2,4-8]. A direct interaction between the two proteins,
each present as high molecular weight multimers, occurs
shortly after entry and is required for downstream in-
hibition of viral replication [8-12]. The mechanism of
TRIM5α-mediated restriction can be broken down to
discrete events, some of them inter-dependent: (i) virus
entrapment into TRIM5α cytoplasmic bodies [13], (ii) de-
creased stability of the virus core [8,14-16], (iii) targeting
to a proteasome-dependent degradation pathway [17-20],
and (iv) inhibition of nuclear transport [17,21,22].
CypA, a host peptidyl-prolyl cis/trans isomerase that is
ubiquitously expressed in tissues, is known to play roles
in both HIV-1 infection of human cells and in HIV-1 re-
striction by TRIM5α in monkey cells. In dividing per-
missive human cells, CypA enhances HIV-1 infectivity
by regulating the disassembly of its core [23-25] inde-
pendently of TRIM5α [26,27]. On the other hand, re-
striction of HIV-1 by simian TRIM5α orthologues is
enhanced by CypA, and inhibition of CypA expression
or of its activity partially rescues infectivity in restrictive
conditions [21,26,28-30]. CypA binds to an exposed
proline-rich loop on the viral CA [31,32] and catalyzes
the isomerisation of the peptide bond G89-P90 [33,34].
The mutation V86M in the CypA-binding loop of HIV-1
CA has been identified as conferring partial resistance to
TRIM5αrh [35]. The mechanism of HIV-1 resistance to
TRIM5αrh conferred by V86M CA was not addressed in
this study. However, it was established that this mutation
in the CypA-binding loop did not disrupt CA-CypA in-
teractions in vitro or in cell cultures [35].
We and others have proposed that point mutations in
the variable region 1 (v1) of TRIM5αhu could confer
HIV-1 restriction capability [36-41]. These mutations
were discovered by mapping of HIV-1 restriction deter-
minants in non-human TRIM5α orthologues [36,39-41]
or through the use of random mutagenesis-based screens
[38,42]. Such antiviral genes are promising candidates for
gene therapy applications, owing to a few key characte-
ristics: (i) They block replication early after virus entry
and before integration can occur; (ii) They are human-like
and thus probably nonimmunogenic; (iii) They inhibit
HIV-1 by a well-established, natural mechanism with little
side effect expected. However, it is currently unknown
whether HIV-1 can acquire resistance to TRIM5αhu mu-
tants. Here we investigate the extent and mechanism of
resistance of the HIV-1 CA mutant V86M to R332G-
R335G TRIM5αhu and other mutants of the v1 domain.
Our data show that this mutation affects physical andfunctional interactions with CypA in order to decrease
HIV-1 sensitivity to TRIM5α while retaining replication-
enhancement functions also conferred by CypA binding.
Results
CA-V86M HIV-1 is partially resistant to restriction by
TRIM5αhu mutant R332G-R335G
We analyzed whether V86M could protect HIV-1 against
restriction by TRIM5αhu mutant R332G-R335G in human
TE671, human Sup-T1 and feline CRFK cells. The choice
of human cells as an experimental model was justified by
the need to gather data in cells representative of the HIV-
1 natural host, while the analysis in cat cells was prompted
by the absence of an endogenous TRIM5α protein in this
species, thus allowing us to analyze restriction in the
absence of potentially interfering effects from the en-
dogenous gene. All the cell lines created were challenged
by wild-type (WT) or V86M HIV-1 NL43-based vectors
(Figure 1). The two vectors had almost identical titers in
non-restrictive human or cat cells. In addition, when those
vector preparations were normalized according to reverse
transcriptase activity or titer in CRFK cells, they were
found to have similar titers in activated human lym-
phocytes or in human M0, M1 and M2 macrophages
(Additional file 1: Figure S1). However, V86M HIV-1NL-
GFP was about 4-times more infectious than its WT coun-
terpart in cells expressing R332G-R335G TRIM5αhu, and
this was true in all the three cell lines tested (Figure 1). In
other words, restriction of V86M HIV-1NL-GFP was 4-
times less efficient than restriction of WT HIV-1NL-GFP.
Restriction of V86M CA HIV-1 by R332G-R335G TRIM5αhu
is independent of cyclophilin A
Although V86 is located in the CypA-binding loop of
HIV-1 CA, this mutant was previously shown to retain
CA binding to CypA [35]. Accordingly, transduction of
lymphocytes and macrophages by V86M HIV-1 was sig-
nificantly affected by treatment with 5 μM of cyclospor-
ine A (CsA), a drug that competes with CA for binding
to CypA (Additional file 1: Figure S1). We nonetheless
hypothesized that the mutation might affect functional
interactions between CypA, TRIM5α and CA. To dir-
ectly analyze the role of CypA in V86M-mediated resist-
ance, we knocked down its expression in TE671 and in
Sup-T1 cells that had been transduced with WT or
R332G-R335G TRIM5αhu or with the empty vector. The
knockdown was efficient for all the TRIM5 variants and
in both cell contexts (Additional file 1: Figure S2). Non-
transduced cells were eliminated by antibiotic treatment,
and cells were then challenged with either WT or V86M
NL4-3 vectors in the presence or absence of 2 μM CsA
(Figure 2). In control permissive cells, replication of both
WT and V86M HIV-1NL-GFP was decreased (25 to 35%)
either by expression of the CypA shRNA or by CsA
TE671









































































Figure 1 V86M mutation in HIV-1 capsid confers partial
resistance against R332G-R335G TRIM5αhu. TE671 (A), Sup-T1
(B) and CRFK (C) cells were transduced with either WT TRIM5αhu,
R332G-R335G TRIM5αhu, or with the “empty” vector as a control.
Following antibiotic selection, cells were infected with multiple
doses (A, B) or with a single dose (C) of WT or V86M HIV-1NL-GFP.
The two viral preparations had similar virion content as determined
by RT assay. The percentage of infected (GFP-positive) cells was
determined two days later by flow cytometry. In (C), infections were
done at a multiplicity of infection of ~0.1 as determined for the WT
virus in parental cells. Bars show the average data from 3 infections
with standard deviations (***, P-value < 0.0001).
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expected, combining CsA treatment and CypA knock-
down had no additional inhibitory effect on HIV-1 repli-
cation in the two cell lines, confirming that CsA inhibits
incoming HIV-1 in human cells by interfering with itsinteractions with CypA [25,27,43]. In TE671 and Sup-T1
cells expressing R332G-R335G TRIM5αhu, replication
of WT HIV-1 was strongly reduced compared with the
control “vector” cells (~50-fold and 20-fold, respectively)
and like before, V86M partly rescued infection of HIV-1
in these cells (5-fold in TE671 cells, 2.5-fold in Sup-T1
cells). CypA knockdown enhanced infectivity of WT
HIV-1NL-GFP by 5-fold in TE671 cells and by 3-fold in
Sup-T1 cells, but had no significant effect on the rep-
lication of the V86M mutant. Likewise, CsA treatment
strongly increased replication of WT HIV-1NL-GFP in
R332G-R335G TRIM5αhu cells (about 10-times in TE671,
5-times in Sup-T1 cells) but had a much smaller effect on
V86M HIV-1NL-GFP (1.5- to 2-fold in both cell lines).
Therefore, replication of V86M CA HIV-1 in cells ex-
pressing R332G-R335G TRIM5αhu was not efficiently res-
cued by depletion or inhibition of CypA.
CsA concentration-dependent assays
In this experimental setting, instead of using a single
volume of HIV-1NL-GFP for all infections as in Figure 2,
we adjusted the amount of virus used for each virus/cell
combination so that approximately 1% of cells were
infected in the absence of drug, and we then repeated
the infection in presence of increasing CsA concentra-
tions (Figure 3). Like before, CsA decreased replication
of both WT and V86M HIV-1NL-GFP in the permissive
control “vector” cells by 30% to 50% in both TE671 cells
(Figure 3A) and Sup-T1 cells (Figure 3B). CsA rescued
replication of WT HIV-1NL-GFP in cells expressing
R332G-R335G TRIM5αhu, by up to 6-fold in TE671 cells
and 8-fold in Sup-T1 cells. In contrast, the impact of the
drug on the restriction of the V86M mutant by this vari-
ant of TRIM5αhu was much smaller: up to 1.5-fold and
2-fold in TE671 and Sup-T1 cells, respectively.
Altogether, data in Figures 2 and 3 show that res-
triction of V86M HIV-1 replication by R332G-R335G
TRIM5αhu is poorly sensitive to the presence of CypA
compared to restriction of the WT control. However,
replication of V86M HIV-1 in permissive human cells
is as much sensitive as WT HIV-1 to the presence of
CypA.
The sensitivity of HIV-1 restriction by TRIM5αhu mutants
to the V86M mutation correlates with its sensitivity to
CsA treatment
Data shown in Figures 1 and 2 revealed that restriction
of HIV-1 by R332G-R335G TRIM5αhu was counteracted
either by the V86M mutation or by CsA treatment, and
suggested that the two interventions had redundant
effects. In order to better characterize the role of CypA
in the TRIM5α resistance conferred by V86M, we ana-
lyzed the effect of this mutation on other mutants of









































































































p < 0.0001 p = 0.0309
p < 0.0001 p = 0.0486
Figure 2 Restriction of CA-V86M HIV-1 by R332G-R335G TRIM5αhu is independent of cyclophilin A. TE671 cells (A) and Sup-T1 cells (B)
transduced with either WT TRIM5αhu, R332G-R335G TRIM5αhu or with the “empty” vector were also transduced with shRNAs targeting CypA or
the non-relevant luciferase mRNAs. Following antibiotic selection, cells were challenged with a single dose of WT or V86M HIV-1NL-GFP, in the
presence or absence of 2 μM CsA. A multiplicity of infection of ~0.2 was used, as determined for the WT virus in parental cells and in the
absence of drug. WT and V86M virus preparations were adjusted by RT assay. Cells were analyzed by FACS two days after infection, and the bars
show the average % infected cells from 3 infections with standard deviations. Note the difference in scale between the y-axis of different graphs.
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R335G, and G330E-R332G-R335G TRIM5αhu all restric-
ted HIV-1 when expressed in TE671 cells, albeit with
various efficacies (Additional file 1: Figure S3A), and
as shown before [38,42]. Replication of HIV-1NL-GFP in
these cells was enhanced either by introducing the
V86M mutation (Additional file 1: Figure S3A) or by
CsA treatment (Additional file 1: Figure S3B). When we
plotted the increase in HIV-1NL-GFP infectivity resul-
ting from V86M against the increase in infectivity
resulting from CsA treatment in TE671 expressing
these various TRIM5αhu, we observed a highly signifi-
cant correlation (Figure 4). Also, the level of rescue
of HIV-1NL-GFP infectivity by either V86M mutation
or CsA treatment was grossly proportional to the
level of restriction. This analysis supports our findings
that V86M and CsA treatment rescue HIV-1 replica-
tion in restrictive conditions by redundant mecha-
nisms. However, the slope of the linear curve (1.89) also
shows that CsA is more efficient than V86M at rescuing
HIV-1 replication.Restriction of V86M CA HIV-1 by R332G-R335G TRIM5αhu
in cat cells is insensitive to CsA
In human cells expressing an HIV-1-restrictive TRIM5α,
CsA treatment might cause dual, opposite effects on
HIV-1: enhancement by counteracting TRIM5α, and in-
hibition by a yet unclear, CypA-dependent mechanism.
In addition, although endogenous TRIM5αhu is thought
to be recessive against the over-expressed TRIM5α in
our experimental system, there was still a slight possi-
bility for interference effects. To address these issues,
we analyzed the rescue of HIV-1 replication by V86M
mutation and/or by CsA treatment under restriction
by R332G-R335G TRIM5αhu in CRFK cat fibroblasts.
These cells do not express any TRIM5α, and CsA
treatment does not inhibit WT HIV-1 infection in cat
cells [26,44]. We found that R332G-R335G TRIM5αhu
strongly restricted HIV-1NL-GFP, and the mutation V86M
in CA decreased restriction by about 3-fold (Figure 5).
WT HIV-1NL-GFP replication was enhanced 10-times
by CsA treatment while the effect of the drug on the
replication of V86M HIV-1NL-GFP was much smaller
TE671



























































Figure 3 CsA dose-dependent analysis. TE671 cells (A) and Sup-
T1 cells (B) expressing R332G-R335G TRIM5αhu or transduced with
the “empty” vector were challenged with WT or V86M HIV-1NL-GFP in
the presence of increasing concentrations of CsA. Virus doses were
adjusted so that approximately 1% of cells were infected in the
absence of CsA. The percentages of infected cells were determined
two days later as before and results are shown as –fold increases
relative to the relevant no-drug controls.








































y = 1.8912x - 0.8305
R² = 0.9653
P = 0.004
Figure 4 Direct correlation between the effect of mutation
V86M and the effect of CsA treatment. The increase in HIV-1
infectivity in TE671 cells expressing the indicated TRIM5αhu in
presence of 2 μM CsA was plotted against the increase in infectivity
resulting from the V86M mutation. All values are –fold increases
relative to the untreated WT control virus. Data were gathered at a
multiplicity of infection yielding close to 1% infected cells for the
untreated WT HIV-1 in the cell lines expressing each the various
TRIM5α. The correlation is significant, as shown by the R2 obtained














































p < 0.0001 p = 0.0212
Figure 5 V86M HIV-1 restriction by R332G-R335G TRIM5αhu in
cat cells is not counteracted by CsA treatment. CRFK cells were
transduced with R332G-R335G TRIM5αhu or with the empty vector
as control and subsequently challenged with a single dose of WT or
V86M HIV-1NL-GFP in presence or absence of 2 μM CsA. Infections
were done at a multiplicity of infection of ~0.2 as determined in
parental cells infected with the WT virus, and the amounts of viruses
used were normalized by RT assay. The percentages of infected cells
were determined two days later by FACS.
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cells.
V86M CA interactions with CypA studied by NMR
Data in Figures 1, 2, 3, 4 and 5 showed that V86M made
HIV-1 resistant to CypA-dependent, TRIM5α-mediated
restriction mechanisms. Thus, we hypothesized that
V86M could modify the interactions between HIV-1 CA
and CypA, or the isomerisation of the former by the
latter [33,45]. The interaction of CA with CypA was
studied by 2D 1H,15N ZZ-exchange NMR spectroscopy
(Figure 6). In the absence of CypA, we observed two
G89 N-H correlation peaks in the V86M capsid spectra,
indicating that, as in WT, the GP bond exists in both cis
and trans states. However, the peak positions for both
states in V86M were chemically shifted compared to
WT, suggesting that the mutation influences the con-
formations adopted by the cyclophilin-binding loop
(Figure 6A). Furthermore, there is evidence of a second
minor G89cis peak in the V86M spectra that is indicative
of discrete CypA-binding loop isomers.
Upon addition of CypA, symmetrical exchange peaks
were observed for WT and V86M indicating that both
capsids are a substrate for CypA and that increased
cis-trans exchange occurs during the ZZ-exchange ex-
periment. However, in the V86M mutant, at least two















































Figure 6 V86M CA interactions with CypA studied by NMR. (A) Expansions of 2D 1H-15N ZZ-exchange spectra illustrating CypA catalysed
cis-trans proline isomerisation of P90 in HIV1caN. The four panels represent backbone amide 1H,15N correlations for the preceding G89 residue in
HIV1caN and in HIV1caN V86M in the presence and absence of CypA. In the absence of CypA, the isomerisation reaction is slow and only distinct
G89 cis- and trans- correlation peaks are observed. The presence of CypA leads to an increase in the isomerisation rate and the accumulation of
cis and trans exchange peaks. The dotted box denotes the location of the exchange peaks and indicates their symmetrical distribution with
regard to G89cis and G89trans. Note that in the case of HIV1caN V86M a broad G89cis peak and an additional cis-exchange peak indicates a
second conformer. All spectra were acquired at the same mixing time (69 ms) and processed with the same contour levels. (B) Evaluation of
exchange rates for CypA catalyzed isomerisation of G89-P90 in HIV1caN and HIV1caN V86M. Normalised peak intensities of trans auto peaks and
the corresponding exchange peaks for HIV1caN/CypA and HIV1caN V86M/CypA were plotted as a function of mixing time (s). Exchange rates (kex)
in the order of 5 s-1 for HIV1caN/CypA and 20 s-1 for HIV1caN V86M/CypA were extracted by fitting auto peaks and exchange peaks as described
by Bosco et al. (2002).
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shapes of these additional peaks were directly affected
by addition of CypA and dependent upon the mixing
time of the experiment (Figure 6B). This supports the
hypothesis that the V86M mutation results in distinct
populations of conformers for the G89-P90 bond.
Next, we determined the catalysed isomerisation rate
of the G89-P90 bond in both WT and V86M capsids in
the presence of CypA (Figure 6B). For WT capsid we
observed a similar rate as previously published, of ~5 s-1.
For the V86M capsid, the exchange rate for the major
G89 peak was ~20 s-1. This suggests that the V86M mu-
tation has both altered the conformations adopted by
the CypA-binding loop and increased the rate at which
it is isomerised. The presence of an additional G89cis
peak in V86M in the absence of CypA suggests that the
mutant capsid may also undergo faster uncatalysed iso-
merisation, however we were not able to quantify this
under the conditions tested.
Effects of V86M on early stages of viral replication
qPCR assays were performed on DNA extracted from
TE671 cells expressing either WT TRIM5αhu, R332G-
R335G TRIM5αhu or, as a positive control, TRIM5αrh,
and then infected with WT or V86M HIV-1NL-GFP
(Figure 7). We quantified GFP DNA as a marker for late
reverse transcription products and 2-LTR circles as a
marker for nuclear viral DNA. As expected, accumula-
tion of HIV-1 DNA was reduced in cells expressing
TRIM5αrh and R332G-R335G TRIM5αhu, and levels of
nuclear HIV-1 DNA were even more strongly decreased.
This is consistent with HIV-1 replication being impeded
by TRIM5α at both the reverse transcription and nuclear

































Figure 7 V86M enhances nuclear transport of HIV-1 DNA in restrictive
challenged with WT or V86M HIV-1NL-GFP. An RT inhibitor (nevirapine) contr
levels of HIV-1 late reverse transcription products and 2-LTR circles were de
2-LTR junctions, respectively. DNA amounts were calculated using serially d
of late RT or 2-LTR DNA copies over the number of GAPDH DNA copies, no
standard deviations of 3 or 5 independent infections (late RT products and
data, specifically WT vs V86M viruses in cells expressing R332G-R335G or TRwere more decreased in TRIM5αrh cells than in R332G-
R335G TRIM5αhu cells, consistent with the greater mag-
nitude of restriction conferred by TRIM5αrh. V86M had
no effect on total DNA levels but significantly increased
relative amounts of 2-LTR nuclear DNA species. How-
ever, V86M 2-LTR DNA levels in restrictive cells were
still reduced 5- to 10-times compared with levels of WT
2-LTR DNA in non-restrictive conditions, as expected
from the observation that V86M only partially rescues
HIV-1 in restrictive conditions. In summary, escape
from restriction by this mutant is associated with
increased HIV-1 transport to the nucleus.
Effect of CypA and V86M on a spreading HIV-1 infection
Single-cycle experiments using HIV-1 vectors are useful
to investigate restriction events taking place between
entry and integration. However, restriction of fully repli-
cating HIV-1 may be more complex than what is reflec-
ted in these assays. Indeed, TRIM5α may also interfere
with late stages of the retroviral cycle [46] although
these conclusions have been rebutted [47]. Perhaps even
more significantly, HIV-1 propagation occurs mainly
through so-called virological synapses forming between
cells [48-50]. It is still unclear whether TRIM5α restricts
HIV-1 originating from these viral synapses in the same
way that it targets incoming capsids from cell-free
viruses, but there are some indications that it does not
[51]. In order to investigate the role of CypA and the ef-
fect of V86M on HIV-1 restriction in a spreading infection
context, we infected Sup-T1 cells with the NL4-3 strain of
HIV-1 (Figure 8). The cell lines included in the experi-
ment expressed R332G or R332G-R335G TRIM5αhu and
were co-transduced with the shRNA against CypA or the



























conditions. TE671 cells expressing the indicated TRIM5α were
ol was included to show the absence of contaminating DNA. The
termined by real-time quantitative PCR using primers to detect GFP or
iluted, linearized DNAs as standards. Data are presented as mean ratio
rmalized to the permissive control TRIM5αhu. Shown are values with
2-LTR, respectively). Student’s t-test was used to test for significance of
IM5α (p = 0.0020 and p = 0.0015, respectively).














































Figure 8 Restriction of a spreading CA-V86M HIV-1 infection. Sup-T1 cells transduced with a control shRNA against luciferase (A) or with an
shRNA targeting CypA (B) and expressing the indicated TRIM5α proteins were infected once with an identical dose of WT or V86M HIV-1NL4-3
normalized by RT activity. Unbound virus was eliminated 16 h later and infection was allowed to proceed for 45 days. Reverse transcriptase
activity in the supernatant of infected cells and of uninfected cells as a control were determined periodically. Background noise as determined
from the uninfected cells was subtracted from the other samples at each time-point.
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monitor replication. Instead, we performed a reverse tran-
scriptase (RT) assay [38]. Replication of WT NL4-3 in the
control (vector) shRNA-Luc cells peaked at about 18 days
post-infection, while replication of the V86M mutant in
the same cells peaked at about 15 days. Thus, V86M
did not affect the fitness of HIV-1 in Sup-T1 cells. Rep-
lication of either WT or V86M NL4-3 was not detectable
in the shRNA-Luc cells also expressing R332G-R335G
TRIM5αhu (Figure 8, top panel). Therefore, if the V86M
mutation conferred some level of resistance to R332G-
R335G TRIM5αhu in a spreading infection context, it did
not do so at levels high enough to allow detection ofreplication. In cells expressing R332G TRIM5αhu, active
replication was detected but only at a single time-point
(day 35 post-infection). Replication of V86M NL4-3 was
not detected in the same cells, which suggests that V86M
does not provide protection against this particular mutant
of TRIM5αhu in a spreading infection assay. In cells
transduced with the shRNA targeting CypA, viral replica-
tion was delayed compared to the control shRNA-Luc
cells, as expected. This was more obvious for the V86M
virus which peaked at about 18 days, confirming that CA-
V86M HIV-1 depends on CypA for optimal replication in
human cells. Interestingly, replication of WT and V86M
NL4-3 in shRNA-CypA/R332G TRIM5αhu-expressing
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the shRNA-Luc cells. Specifically, replication of WT NL4-
3 peaked at 28 days post-infection, compared to 35 days
post-infection in the control cells, and the amount of
viruses in the supernatants was also much higher. V86M
NL4-3 peaked at about 35 days post-infection in the
shRNA-CypA/R332G TRIM5αhu-expressing cells while its
replication was not detected in the shRNA-Luc/R332G
cells. This suggests that CypA knockdown can rescue rep-
lication of these two viruses in TRIM5-restrictive con-
ditions and also that V86M NL4-3 is more sensitive to
restriction by R332G TRIM5αhu, in contradiction with the
data obtained in vector transduction experiments. In
shRNA-CypA/R332G-R335G TRIM5αhu-expressing cells,
replication of both WT and V86M NL4-3 was detected,
although at low levels. Replication of V86M NL4-3 was no
more efficient than that of its WT counterpart in these
cells. Altogether, this experiment shows that restriction of
a spreading HIV-1 infection by mutant TRIM5αhu in Sup-
T1 cells is enhanced by CypA, and suggests that the
V86M mutation does not rescue HIV-1 replication in this
context.
Discussion
HIV-1 resistance to treatment is a hallmark of pharma-
cological interventions against this virus. Invariably, mu-
tations appear in the coding sequences of the proteins
targeted by antiretroviral drugs, including protease, re-
verse transcriptase and integrase [52]. It is expectable
that genetic interventions will similarly lead to the oc-
currence of viral resistance. Indeed, restriction of HIV-1
by CPSF6-358, a truncated form of the RNA processing
factor, cleavage and polyadenylation specific factor 6
(CPSF6), is counteracted by the mutation N74D in CA
[53]. This mutation, isolated by serial passages of HIV-1
in cells expressing CPSF6-358, abrogates direct binding
of CA to CPSF6-358 [54]. Several groups, including
ours, have produced mutants of TRIM5αhu to be used as
antiviral transgenes [36,38-41]. In order to predict po-
tential HIV-1 escape from inhibition mediated by these
TRIM5αhu variants, it is important to isolate those es-
cape mutants in vitro, and to understand by which
mechanism they decrease sensitivity to restriction. Our
initial efforts had not led us to isolate R332G-R335G
TRIM5αhu-resistant HIV-1 by serial passaging. We then
decided to test whether V86M, an HIV-1 CA mutant
isolated from cells expressing TRIM5αrh by the Sodroski
group and shown to confer some level of protection
against this orthologue, would also make HIV-1 resistant
to TRIM5αhu mutants.
Our data show that V86M indeed confers some level
of protection against various mutants of TRIM5αhu, at
least in the context of single-cycle infections with HIV-1
vectors. We saw no protection in the context of HIV-1spreading infections, although we tested only one HIV-1
strain (NL4-3) in one cell line (Sup-T1). Sodroski and
collaborators [35] have isolated the V86M mutant in
HeLa-CD4 cells, which we have not tested here. They
observed modest levels (2-fold) of protection against
TRIM5αrh in these HeLa-derived cells when infectivity
was measured in single-cycle assays, and they saw an
even more modest effect in canine Cf2Th cells [35].
Altogether, V86M can confer HIV-1 protection against
restriction by various TRIM5α proteins in specific repli-
cation settings. However, even in situations in which
protection takes place, restriction still occurs, albeit wea-
kened. On the basis of our data, we do not expect V86M
to be highly significant in an in vivo context, although
this is of course rather hazardous to predict.
In order to investigate the mechanism of CA-V86M
HIV-1 resistance to R332G-R335G TRIM5αhu, we ana-
lyzed the role of CypA in the restriction. Altogether, our
results show that restriction of V86M CA HIV-1 is
largely insensitive to the presence of functional CypA,
while the same virus is still inhibited in human cells de-
void of CypA. In other words, HIV-1 is able to subtly
alter its interactions with CypA in order to downregulate
a mechanism of restriction while preserving other be-
nefits associated with this interaction. Accordingly, our
NMR data showed that the molecular interactions bet-
ween CA and CypA were altered by the V86M mutation,
as was the isomerisation reaction catalysed by CypA.
Finally, our qPCR data correlate modifications in
CypA-CA interactions with effects on nuclear transport
in restrictive conditions. Interestingly, experiments pre-
dating the discovery of TRIM5α restriction had demons-
trated that CsA treatment of Old World monkey cells
increased nuclear transport of HIV-1 in these cells [21].
More recently, Lin and Emerman similarly observed that
CsA treatment of the sMAGI Rhesus macaque cell line
increases HIV-1 nuclear transport more than it does
enhance reverse transcription [55]. Other recently pub-
lished data also link nuclear transport and CA-CypA in-
teractions in permissive human cells. Specifically, CypA
knockdown and CsA treatment reduce HIV-1 dependency
toward nucleopore components Nup153 and Nup358 for
its nuclear transport [56,57]. It should be informative to
analyze whether V86M modifies the interactions between
HIV-1 CA and these nucleoporins.
Conclusions
The V86M mutation in HIV-1 CA can confer partial resis-
tance against restriction of HIV-1 replication by mutants
of human TRIM5α. V86M abrogates CypA-dependent re-
striction mechanisms, resulting in an increase of HIV-1
DNA nuclear transport in restrictive conditions. However,
this mutation might not confer significant resistance to
the restriction of a spreading HIV-1 infection.
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Plasmid DNAs
pMIP-TRIM5αhu and pMIP-TRIM5αrh express C-ter-
minal FLAG-tagged versions of the corresponding
proteins and have been extensively described before
[28,38,44,58,59]. pMIP-TRIM5αhu with the mutation
R332G-R335G has been described [38], and additional
mutants have been described as well [42]. pSRBl-CypA
expresses a short hairpin RNA (shRNA) targeting the
human CypA mRNA. Shortly, it is the previously des-
cribed pSRP-CypA plasmid [27] in which the puromycin
resistance cassette has been changed to one conferring
resistance to blasticidin. The control plasmid, pSRBl-Luc,
encodes a shRNA targeting luciferase [60]. pNL-GFP,
pMD-G and pCL-Eco have all been described else-
where [21,28,58,61-63]. The fully replication-competent
HIV-1 clone pNL4-3 [64] was used for propagation
experiments.Cells
Human rhabdomyosarcoma TE671 cells, human embry-
onic kidney 293 T cells and feline renal CRFK cells were
maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum and antibiotics
at 37°C. Human T lymphoblast Sup-T1 cells and mo-
nocytic cells THP-1 were maintained in RPMI-1640
supplemented with 10% fetal bovine serum and antibio-
tics at 37°C. All cell culture reagents were from Hyclone
(Thermo Scientific, Logan, UT, USA). Human PBMCs
were isolated from diluted whole blood of a healthy
donor by Ficoll density gradient centrifugation as previ-
ously described [65]. CD4+ T cells were then isolated
using a negative isolation kit (Dynabeads Untouched
Human CD4 T Cells, Invitrogen) according to manufac-
turer specifications. The isolated cells were cultivated in
RPMI-1640 supplemented with 10% fetal bovine serum
and antibiotics. Activation and proliferation of CD4+ T
cells were performed by supplementing the culture
medium with 60 U/ml IL-2 (Peprotech, Canada) and in-
cubating the cells with anti-CD3/CD28 coated beads
(Dynabeads Human T-Activator CD3/CD28, Invitrogen)
according to the manufacturer instructions. Infections of
these cells were performed in the absence of IL-2 and
activating beads. THP-1 monocytic cells (7.5 x 105) were
differentiated into M0 macrophages by incubation in
serum-free medium supplemented with 50 ng/ml PMA
and 10 ng/ml GM-CSF for 48 h. Polarization into pro-
inflammatory M1 macrophages was induced by addition
of 100 ng/ml LPS and 25 U/ml IFN-γ. Anti-inflam-
matory M2 macrophages were induced by addition of
20 ng/ml IL-4 and 20 ng/ml IL-10 (all reagents were
from Peprotech). In all cases, non-adherent cells were
washed away before infection.Retroviral vectors production
HIV-1 and MLV-based vectors were produced through
transient transfection of 293 T cells and collected as pre-
viously described [38,44]. To produce HIV-1NL-GFP, cells
were co-transfected with pNL-GFP and pMD-G. To pro-
duce the MLV-based vectors SRBl and MIP, cells were
transfected with the relevant pMIP or pSRBl plasmid
and co-transfected with pCL-Eco and pMD-G. To pro-
duce HIV-1 VLPs, cells were co-transfected with pΔR8.9
and pMD-G. When necessary, amounts of viruses were
normalized using the nonradioactive EnzChek RT Assay
Kit (Invitrogen, Burlington, ON), or based on their titer
in permissive human cells.
RNA interference
pSRBl-based retroviral vectors encoding an shRNA tar-
geting either CypA or Luc mRNAs were produced in
293 T cells as described [28,38]. TE671 and Sup-T1 cells
were plated at 250,000 cells per well in 12-well plates
and exposed to 1 mL of either SRBL-CypA or -Luc vec-
tor preparation. Two days post-transduction, cells were
placed in medium containing 10 μg/ml of blasticidin
(Sigma-Aldrich). Selection was allowed to proceed for
1 week. Efficiency of the knockdown was verified by
assaying CypA expression levels in the transduced cells
by western blotting, using antibodies directed against
CypA (rabit polyclonal IgG; Sigma-Aldrich, StLouis, MI)
and actin (mouse monoclonal; Chemicon International).
Viral challenges
Cells were plated in 24-well plates at 50,000 cells/well
(TE671 and CRFK), 100,000 cells/well (Sup-T1), 200,000
cells/well (primary CD4 T cells) or 750,000 cells/well
(differentiated THP-1) and infected with HIV-1 vectors
(either HIV-1TRIP-CMV-GFP or HIV-1NL-GFP) with or with-
out CsA treatment (2 or 5 μM). Drugs were added
15 min prior to infections. In CsA dose-dependent ex-
periments, virus doses were adjusted for each virus-cell
combination so that approximately 1% of the cells would
be infected in the absence of CsA. Two days post-in-
fection, cells were trypsinised when necessary, fixed in 1
to 2% formaldehyde in a PBS solution. The % of GFP-
positive cells were then determined by analyzing 10,000
to 20,000 cells with a FC500 MPL cytometer (Beckman
Coulter) using the CXP software (Beckman Coulter). For
spreading infections, quantification of RT activity in
the supernatants of infected cells was done exactly as
before [38].
Quantitative real-time PCR of HIV-1 DNA
Cells were plated in 12-well plates at 3x105 cells/well
and infected with HIV-1NL-GFP WT or V86M vectors.
Viruses were passed through 0.45 μm filters and pre-
treated for 1 hour at 37°C with 20U/ml DNAse I
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carry-over plasmid DNA. In addition, control infections
were performed in presence of 80 μM nevirapine to ascer-
tain the absence of such contaminating plasmid DNA.
Total cellular DNA was prepared after 6 hours of infection
(late RT products) or 6 hours of infection followed by 18 -
hours of incubation in virus-free medium (2LTR-circles)
and DNA preparation was done using the DNeasy Blood
and Tissue Kit (Qiagen, California).
The primer sets to detect each DNA species were as
follows: GFP forward, GACGACGGCAACTACAAGAC;
GFP reverse, TCGTCCATGCCGAGAGTGAT; 2LTR-
circles forward (MH535), AACTAGGGAACCCACTG
CTTAAG [66]; 2LTR-circles reverse (MH536), TCCA
CAGATCAAGGATATCTTGTC; GAPDH forward, GT
CAGTGGTGGACCTGACCT; GAPDH reverse, TGAG
CTTGACAAAGTGGTCG. In each experiment, a stand-
ard curve of the amplicon being measured was run in
duplicate ranging from 30 to 3 × 105 copies plus a no-
template control. Reactions contained 1× SensiFAST
SYBR Lo-Rox kit (Bioline, UK), 300nM forward and re-
verse primers, and 5 μl template DNA (100-300 ng) in
20 μl-sized reactions. After initial incubation step of
3 min at 95°C, 40 cycles of amplification were carried
out at 10s at 95°C, 10s at 62°C (GFP) or 65°C (2LTR,
GAPDH) and 10s (GFP) or 15 s (2LTR, GAPDH) at
72°C on a MX3000P qPCR system (Agilent Technolo-
gies, California). Results were analyzed with the MxPro
software (Agilent Technologies).
Statistical analyses
Statistical data were calculated using GraphPad Prism
version 5.03. Student’s unpaired t-tests were used for
tests of difference between means.
2D 1H-15 N Heteronuclear (ZZ) Exchange Spectroscopy
Uniformly 15 N-labeled CAN domain of HIV1 (15 N
HIV1caN) was expressed in DE3 bacteria in K-MOPS
buffer supplemented with 20 mM 15NH4Cl as a sole
source of nitrogen, 4 mM pH 8.0 KPOi, 0.1 o/oo sodium
ampicillin salt, vitamins and 0.4% glucose. Bacterial cul-
ture was grown until 0.500-0.700 OD600 at 37°C, indu-
ced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG), and the protein was expressed at 20°C overnight
followed by purification as previously described [67] ex-
cept that the final step of purification, i.e. gel filtration,
was run in 50 mM potassium phosphate, pH 6.5,
100 mM NaCl and 1 mM DTT. Uniformly 15 N-labeled
CAN domain of HIV1 V86M (15 N HIV1caN V86M) was
expressed and purified as per 15 N HIV1caN. Non-iso-
topically labeled N-terminally his6-tagged human CypA
was expressed in DE3 bacteria in 2xTY medium sup-
plemented with 0.6% glucose and 0.1 o/oo sodium ampi-
cillin salt, induced at 0.6-0.8 OD600 at 37°C with 1 mMIPTG, expressed at 20°C and purified using Ni-NTA beads
(Qiagen) and gel-filtration chromatography in 75 mM Tris
pH8.0, 50 mM NaCl and 1 mM DTT buffer. For all NMR
experiments, proteins were dialysed against the same
50 mM KPOi, pH 6.5 buffer and supplemented with
1 mM DTT. The capsids were used at 12-fold excess con-
centration over CypA as previously described [33,68]:
430 μM CAN/35 μM Cyp A or 430 μM CAN only. All
NMR samples contained 5% D2O.
2D 1H-15N heteronuclear (ZZ) exchange experiment is
described in detail in [69] and was previously applied for
a similar model [33,68]. The experiments were per-
formed on a Bruker 800 MHz spectrometer at 298 K
using in-house written pulse program with the following
mixing times in a randomised order: 3 ms, 25 ms,
47 ms, 69 ms, 75 ms, 97 ms, 147 ms, 169 ms, 197 ms,
247 ms, 297 ms, 397 ms, 547 ms and 796 ms. The first
time-point was acquired twice to assess the error. G89
assignment for 15 N HIV1caN was assumed from ppm
chemical shifts referred to in [33,68]. It was also as-
sumed that chemical shifts for G89 in 15 N HIV1caN
V86M did not change dramatically. The data was pro-
cessed in TopSpin 2.0 (Bruker, Karlsruhe) and after
analysis in Sparky (T. D. Goddard and D. G. Kneller,
University of California, San Francisco).
Additional file
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restriction of HIV-1 by additional mutants of TRIM5αhu.
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